The NIDA Avenir award in genetics or epigenetics of substance use disorders

IF 2.6 3区医学 Q3 NEUROSCIENCES

Molecular and Cellular Neuroscience Pub Date : 2023-09-20 DOI:10.1016/j.mcn.2023.103899

John S. Satterlee , Jonathan D. Pollock , Nora D. Volkow

引用次数: 0

Abstract

NIDA's Avenir Program in the Genetics or Epigenetics of Substance Use Disorders (SUDs) was launched to support early stage investigators who propose innovative, high risk, but potentially high impact research and who show promise of being tomorrow's leaders in this scientific field. Since 2015, NIDA has supported 30 Avenir Investigators with unique expertise and creative ideas. This special issue showcases how some of these ideas have germinated, flourished, and borne fruit. In this perspective article we briefly describe the purpose and implementation of the Avenir award and provide a high altitude overview of the awardees and their scientific projects to date.

查看原文本刊更多论文

NIDA Avenir物质使用障碍遗传学或表观遗传学奖。

NIDA的物质使用障碍遗传学或表观遗传学Avenir项目旨在支持早期研究人员，他们提出了创新、高风险但潜在的高影响研究，并有望成为该科学领域的未来领导者。自2015年以来，NIDA已经为30名Avenir调查员提供了独特的专业知识和创意支持。这期特刊展示了其中一些想法是如何萌芽、蓬勃发展并结出果实的。在这篇前瞻性的文章中，我们简要描述了Avenir奖的目的和实施，并对获奖者及其迄今为止的科学项目进行了高海拔概述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and Cellular Neuroscience 医学-神经科学

CiteScore

5.60

自引率

0.00%

发文量

审稿时长

37 days

期刊介绍： Molecular and Cellular Neuroscience publishes original research of high significance covering all aspects of neurosciences indicated by the broadest interpretation of the journal''s title. In particular, the journal focuses on synaptic maintenance, de- and re-organization, neuron-glia communication, and de-/regenerative neurobiology. In addition, studies using animal models of disease with translational prospects and experimental approaches with backward validation of disease signatures from human patients are welcome.